Trifluridine/Tipiracil Hydrochloride

Phase 2Small molecule

Institut de Recherches Internationales Servier

Trifluridine/Tipiracil Hydrochloride is one of 54 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerRecruiting

Total Neoadjuvant TherapyNot yet recruiting

Metastatic Colorectal CancerPhase 2

Recruiting

Total Neoadjuvant TherapyPhase 2

Not yet recruiting

Competition

Competitive Landscape

144 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

20 2

Opdivo

Bristol-Myers Squibb

Phase 3

13 3

Braftovi

Pfizer

Phase 3

11 4

Tecentriq

Roche

Phase 3

10 5

Yervoy

Bristol-Myers Squibb

Phase 3

7 6

Bayer Aspirin

Bayer

Phase 3

2 7

Lumakras

Amgen

Phase 3

1 8

FOLFOX

AstraZeneca

Phase 3

14 9

Trifluridine/tipiracil

AbbVie

Phase 3

11 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Metastatic Colorectal Cancer

NCT03869892

Q2 2028

Phase 2Not yet recruiting

Total Neoadjuvant Therapy

NCT06872606

Q4 2032

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT05007132

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer3 trials

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

Active, not recruiting· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 3·NCT03869892·856 enrolled

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1·NCT02848443·78 enrolled

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Recruiting·DDominik Paul Modest·Phase 2·NCT05007132·153 enrolled

Total Neoadjuvant Therapy1 trial

Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer

Not yet recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06872606·33 enrolled

Colorectal Cancer1 trial

A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 3·NCT03306394·907 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Trifluridine/Tipiracil Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trifluridine/Tipiracil Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trifluridine/Tipiracil Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut de Recherches Internationales Servier company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Institut de Recherches Internationales Servier

Trifluridine/Tipiracil Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Q4 2032

Trials by Indication[1]

Metastatic Colorectal Cancer3 trials

Total Neoadjuvant Therapy1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News